Ae1 Ae3 Antibody Bafilomycin A1 Bile Acid Assay Bioassay Blog Ch 223191 Choline Acetyltransferase Antibody Ldn 193189 Medium Mip 1B peptide Polyclonal Purification Ru 58841 Trypsin Activity Assay Tubastatin A Uric Acid Assay Valproic Acid Sodium Salt Western Blot
Reconstitution of the destruction complex defines roles of AXIN polymers and APC in β-catenin capture, phosphorylation, and ubiquitylation
The Wnt/β-catenin pathway is a extremely conserved, incessantly mutated developmental and most cancers pathway. Its output is outlined primarily by β-catenin’s phosphorylation- and ubiquitylation-dependent proteasomal degradation, initiated by the multi-protein β-catenin destruction advanced.
The exact mechanisms underlying destruction advanced perform have remained unknown, largely due to the shortage of appropriate in vitro techniques. Right here we describe the in vitro reconstitution of an energetic human β-catenin destruction advanced from purified parts, recapitulating advanced meeting, β-catenin modification, and degradation.
We reveal that AXIN1 polymerization and APC promote β-catenin seize, phosphorylation, and ubiquitylation. APC facilitates β-catenin’s flux by the advanced by limiting ubiquitylation processivity and straight interacts with the SCFβ-TrCP E3 ligase advanced in a β-TrCP-dependent method.
Oncogenic APC truncation variants, though a part of the advanced, are functionally impaired. Nonetheless, even essentially the most severely truncated APC variant promotes β-catenin recruitment. These findings exemplify the ability of biochemical reconstitution to interrogate the molecular mechanisms of Wnt/β-catenin signaling.
A Community Pharmacology Strategy to Examine the Mechanism of Erjing Prescription in Sort 2 Diabetes
Erjing prescription (EJP) was an historical system that was recorded within the Normal Medical Assortment of Royal Benevolence of the Track Dynasty. It has been incessantly used to deal with sort 2 diabetes mellitus (T2DM) within the lengthy historical past of China.
The system consists of Lycium barbarum L. and Polygonatum sibiricum F. Delaroche with a ratio of 1 : 1. This examine aimed to establish the potential results and mechanisms of EJP remedy T2DM. The goal proteins and potential pathways of EJP in T2DM remedy have been investigated by the strategy of community pharmacology and real-time PCR (RT-PCR).
99 diabetes-related proteins have been regulated by 56 bioactive constituents in EJP in 26 sign pathways by Cytoscape dedication. In accordance with GO evaluation, 606 genes entries have been enriched. The PPI community prompt that AKT1, EGF, EGFR, MAPK1, and GSK3β proteins have been core genes. Among the many 26 sign pathways, the PI3K-AKT sign pathway was examined by the RT-PCR.
The expression stage of PI3K p85, AKT1, GSK3β, and Myc mRNA of this pathway was regulated by EJP. The examine based mostly on community pharmacology and RT-PCR evaluation revealed that the blood sugar stage was regulated by EJP by way of regulating the PI3K-AKT sign pathway. Loads of new remedy strategies for T2DM utilizing EJP have been supplied by community pharmacology evaluation.
Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
Acquired resistance to MAPK inhibitors limits the medical efficacy in melanoma remedy. We and others have lately proven that BRAF inhibitor (BRAFi)-resistant melanoma cells can develop a dependency on the therapeutic medication to which they’ve acquired resistance, making a vulnerability for these cells that may probably be exploited in most cancers remedy.
In drug-addicted melanoma cells, it was proven that this induction of cell loss of life was preceded by a particular ERK2-dependent phenotype change; nevertheless, the underlying molecular mechanisms are largely missing.
To extend the molecular understanding of this drug dependency, we utilized a mass spectrometry-based proteomic strategy on BRAFi-resistant BRAFMUT 451Lu cells, during which ERK1, ERK2, and JUNB have been silenced individually utilizing CRISPR-Cas9.
Inactivation of ERK2 and, to a lesser extent, JUNB prevents drug dependancy in these melanoma cells, whereas, conversely, knockout of ERK1 fails to reverse this phenotype, exhibiting a response much like that of management cells.
Our evaluation reveals that ERK2 and JUNB share comparable proteome responses dominated by reactivation of cell division. Importantly, we discover that EMT activation in drug-addicted melanoma cells upon drug withdrawal is affected by silencing ERK2 however not ERK1.
Furthermore, transcription issue (regulator) enrichment reveals that PIR acts as an effector of ERK2 and phosphoproteome evaluation reveals that silencing of ERK2 however not ERK1 results in amplification of GSK3 kinase exercise. Our outcomes depict potential mechanisms of drug dependancy in melanoma, which can present a information for therapeutic methods in drug-resistant melanoma.
Inhibition of AKT Signaling Alters βIV Spectrin Distribution on the AIS and Will increase Neuronal Excitability
The axon preliminary section (AIS) is a extremely regulated subcellular area required for neuronal firing. Adjustments within the AIS protein composition and distribution are a type of structural plasticity, which powerfully regulates neuronal exercise and will underlie a number of neuropsychiatric and neurodegenerative problems.
Regardless of its physiological and pathophysiological relevance, the signaling pathways mediating AIS protein distribution are nonetheless poorly studied. Right here, we used confocal imaging and whole-cell patch clamp electrophysiology in main hippocampal neurons to check how AIS protein composition and neuronal firing diversified in response to chose kinase inhibitors focusing on the AKT/GSK3 pathway, which has beforehand been proven to phosphorylate AIS proteins.
Picture-based options representing the mobile sample distribution of the voltage-gated Na+ (Nav) channel, ankyrin G, βIV spectrin, and the cell-adhesion molecule neurofascin have been analyzed, revealing βIV spectrin as essentially the most delicate AIS protein to AKT/GSK3 pathway inhibition.
Inside this pathway, inhibition of AKT by triciribine has the best impact on βIV spectrin localization to the AIS and its subcellular distribution inside neurons, a phenotype that Assist Vector Machine classification was in a position to precisely distinguish from management.
Therapy with triciribine additionally resulted in elevated excitability in main hippocampal neurons. Thus, perturbations to signaling mechanisms throughout the AKT pathway contribute to adjustments in βIV spectrin distribution and neuronal firing that could be related to neuropsychiatric and neurodegenerative problems.
Copper publicity induces hepatic G0/G1 cell-cycle arrest by suppressing the Ras/PI3K/Akt signaling pathway in mice
Copper (Cu), as a typical chemical contaminant in surroundings, is understood to be poisonous at excessive concentrations. The present analysis demonstrates the results of copper upon hepatocyte cell-cycle development (CCP) in mice. Institute of most cancers analysis (ICR) mice (n = 240) at an age of 4 weeks have been divided randomly into teams handled with totally different doses of Cu (0, 4, 8, and 16 mg/kg) for 21 and 42 days.
anti- GSK3B antibody |
|||
| FNab03674 | FN Test | 100µg | EUR 505.25 |
|
Description: Antibody raised against GSK3B |
|||
anti- GSK3B antibody |
|||
| FNab03675 | FN Test | 100µg | EUR 585 |
|
Description: Antibody raised against GSK3B |
|||
anti- GSK3B antibody |
|||
| FNab03676 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against GSK3B |
|||
Anti-GSK3B antibody |
|||
| PAab03673 | Lifescience Market | 100 ug | EUR 355 |
Anti-GSK3B antibody |
|||
| PAab03674 | Lifescience Market | 100 ug | EUR 355 |
Anti-GSK3B antibody |
|||
| PAab03675 | Lifescience Market | 100 ug | EUR 412 |
Anti-GSK3B antibody |
|||
| PAab03676 | Lifescience Market | 100 ug | EUR 386 |
Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 349 |
Anti-GSK3B Antibody (Biotin) |
|||
| STJ501296 | St John's Laboratory | 100 µg | EUR 586 |
Anti-GSK3B Antibody (FITC) |
|||
| STJ501297 | St John's Laboratory | 100 µg | EUR 586 |
anti-GSK3B (3D10) |
|||
| LF-MA30340 | Abfrontier | 100 ul | EUR 486 |
|
Description: Mouse Monoclonal to GSK3B |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 521 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 723 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 533 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 740 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 557 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 775 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Hu-48T | DL Develop | 48T | EUR 517 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Hu-96T | DL Develop | 96T | EUR 673 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Mu-48T | DL Develop | 48T | EUR 527 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Mu-96T | DL Develop | 96T | EUR 688 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Ra-48T | DL Develop | 48T | EUR 549 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Ra-96T | DL Develop | 96T | EUR 718 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 544 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 756 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 557 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 774 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 583 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 811 |
Anti-Phospho-GSK3B-(S9) antibody |
|||
| STJ22160 | St John's Laboratory | 100 µl | EUR 393 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Phospho-GSK3B-(Y216) antibody |
|||
| STJ116370 | St John's Laboratory | 100 µl | EUR 393 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Phospho-GSK3B-(Y216) antibody |
|||
| STJ110852 | St John's Laboratory | 100 µl | EUR 393 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-GSK3b (Ab-9) Antibody |
|||
| A00791-1 | BosterBio | 100ul | EUR 397 |
|
Description: Rabbit Polyclonal GSK3b (Ab-9) Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat. |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009038 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat, Pig. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA002848 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IP, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IP:2-5ug/mglysate.ELISA:1/20000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA080166 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC;WB:1:1000-2000.IHC:1:200-500 |
|||
GSK3B Antibody |
|||
| CSB-PA939628- | Cusabio | EUR 335 | |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| CSB-PA939628-100ul | Cusabio | 100ul | EUR 316 |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| 36918-100ul | SAB | 100ul | EUR 252 |
GSK3B antibody |
|||
| 38353-100ul | SAB | 100ul | EUR 252 |
GSK3B antibody |
|||
| 38616-100ul | SAB | 100ul | EUR 252 |
GSK3B Antibody |
|||
| ABD6806 | Lifescience Market | 100 ug | EUR 438 |
GSK3B Antibody |
|||
| ABD7231 | Lifescience Market | 100 ug | EUR 438 |
GSK3B Antibody |
|||
| DF7231 | Affbiotech | 200ul | EUR 304 |
|
Description: GSK3B Antibody detects endogenous levels of total GSK3B. |
|||
GSK3B Antibody |
|||
| BF0695 | Affbiotech | 200ul | EUR 376 |
|
Description: GSK3B antibody detects endogenous levels of total GSK3B. |
|||
GSK3B antibody |
|||
| 10R-1862 | Fitzgerald | 100 ul | EUR 403 |
|
Description: Mouse monoclonal GSK3B antibody |
|||
GSK3B antibody |
|||
| 70R-17615 | Fitzgerald | 50 ul | EUR 435 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3b antibody |
|||
| 70R-11869 | Fitzgerald | 100 ug | EUR 418 |
|
Description: Rabbit polyclonal GSK3b antibody |
|||
GSK3B antibody |
|||
| 70R-15005 | Fitzgerald | 100 ul | EUR 392 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3A/GSK3B Antibody |
|||
| 1-CSB-PA002838 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3A/GSK3B. Recognizes GSK3A/GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000 |
|||
GSK3B (pY216) Antibody |
|||
| 20-abx123289 | Abbexa |
|
|
GSK3B (pY216) Antibody |
|||
| 20-abx000312 | Abbexa |
|
|
GSK3B Polyclonal Antibody |
|||
| A62706 | EpiGentek | 100 µg | EUR 570.55 |
|
Description: reagents widely cited |
|||
GSK3A / GSK3B Antibody |
|||
| 20-abx328487 | Abbexa |
|
|
GSK3B Conjugated Antibody |
|||
| C36918 | SAB | 100ul | EUR 397 |
GSK3B Conjugated Antibody |
|||
| C38353 | SAB | 100ul | EUR 397 |
Phospho-GSK3b antibody |
|||
| 70R-11870 | Fitzgerald | 100 ug | EUR 525 |
|
Description: Rabbit polyclonal Phospho-GSK3b antibody |
|||
Sheep Anti Fitc Polyclonal Antibody,Alk. Phos. |
|||
| DPBT-68234SF | Creative Diagnostics | 1 ml | EUR 741 |
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 280 |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 280 |
GSK3B siRNA |
|||
| 20-abx918789 | Abbexa |
|
|
GSK3B siRNA |
|||
| 20-abx918790 | Abbexa |
|
|
GSK3B siRNA |
|||
| 20-abx902344 | Abbexa |
|
|
GSK3B Plasmid |
|||
| PVT7113 | Lifescience Market | 2 ug | EUR 266 |
Phospho-GSK3B (S9) Antibody |
|||
| 1-CSB-PA000536 | Cusabio |
|
|
|
Description: A polyclonal antibody against Phospho-GSK3B (S9). Recognizes Phospho-GSK3B (S9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IP, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IP:2-5ug/mglysate.ELISA:1/5000 |
|||
Phospho-GSK3B (S9) Antibody |
|||
| 1-CSB-PA000636 | Cusabio |
|
|
|
Description: A polyclonal antibody against Phospho-GSK3B (S9). Recognizes Phospho-GSK3B (S9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/10000 |
|||
GSK3B Antibody, HRP conjugated |
|||
| 1-CSB-PA009963LB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
GSK3B Antibody, FITC conjugated |
|||
| 1-CSB-PA009963LC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
GSK3B Antibody, Biotin conjugated |
|||
| 1-CSB-PA009963LD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
GSK3B (Ab-9) Antibody |
|||
| CSB-PA120951- | Cusabio | EUR 335 | |
|
Description: A polyclonal antibody against GSK3B (Ab-9). Recognizes GSK3B (Ab-9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:200, IF:1:100-1:200 |
|||
GSK3B (Ab-9) Antibody |
|||
| CSB-PA120951-100ul | Cusabio | 100ul | EUR 316 |
|
Description: A polyclonal antibody against GSK3B (Ab-9). Recognizes GSK3B (Ab-9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:200, IF:1:100-1:200 |
|||
Phospho-GSK3B (Ser9) Antibody |
|||
| CSB-PA166926- | Cusabio | EUR 335 | |
|
Description: A polyclonal antibody against Phospho-GSK3B (Ser9). Recognizes Phospho-GSK3B (Ser9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200 |
|||
Phospho-GSK3B (Ser9) Antibody |
|||
| CSB-PA166926-100ul | Cusabio | 100ul | EUR 362 |
|
Description: A polyclonal antibody against Phospho-GSK3B (Ser9). Recognizes Phospho-GSK3B (Ser9) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200 |
|||
GSK3B (pS21 / 29) Antibody |
|||
| abx031864-400ul | Abbexa | 400 ul | EUR 523 |
GSK3B (pS21 / 29) Antibody |
|||
| abx031864-80l | Abbexa | 80 µl | EUR 286 |
GSK3B Polyclonal Conjugated Antibody |
|||
| C30706 | SAB | 100ul | EUR 397 |
Rabbit Anti-GSK3B monoclonal antibody, clone TZ13-82 |
|||
| DCABH-9320 | Creative Diagnostics | 100 ul | EUR 777 |
Rabbit Anti-Human GSK3B Polyclonal Antibody, Phospho-Tyr216 |
|||
| CPB-820RH | Creative Diagnostics | 100 ul | EUR 559 |
PolyTek, Anti-Rabbit Polymerized Alk-Phos |
|||
| PAL008 | ScyTek Laboratories | 8 ml | EUR 133 |
PolyTek, Anti-Rabbit Polymerized Alk-Phos |
|||
| PAL015 | ScyTek Laboratories | 15 ml | EUR 197 |
PolyTek, Anti-Rabbit Polymerized Alk-Phos |
|||
| PAL125 | ScyTek Laboratories | 125 ml | EUR 909 |
PolyTek, Anti-Rabbit Polymerized Alk-Phos |
|||
| PAL500 | ScyTek Laboratories | 500 ml | EUR 3199 |
PolyTek, Anti-Rabbit Polymerized Alk-Phos |
|||
| PAL999 | ScyTek Laboratories | 1000 ml | EUR 5776 |
PolyTek Anti-Mouse Polymerized Alk-Phos |
|||
| PAT008 | ScyTek Laboratories | 8 ml | EUR 133 |
PolyTek Anti-Mouse Polymerized Alk-Phos |
|||
| PAT015 | ScyTek Laboratories | 15 ml | EUR 197 |
PolyTek Anti-Mouse Polymerized Alk-Phos |
|||
| PAT125 | ScyTek Laboratories | 125 ml | EUR 909 |
PolyTek Anti-Mouse Polymerized Alk-Phos |
|||
| PAT500 | ScyTek Laboratories | 500 ml | EUR 3199 |
PolyTek Anti-Mouse Polymerized Alk-Phos |
|||
| PAT999 | ScyTek Laboratories | 1000 ml | EUR 5776 |
Rabbit anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0121 | Fitzgerald | 1 mg | EUR 399 |
|
Description: Rabbit anti Bovine IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0135 | Fitzgerald | 1 mg | EUR 375 |
|
Description: Rabbit anti Bovine IgG secondary antibody (Alk Phos) |
|||
Goat anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0142 | Fitzgerald | 1 mg | EUR 369 |
|
Description: Goat anti Bovine IgG secondary antibody (Alk Phos) |
|||
Goat anti Cat IgG (Alk Phos) |
|||
| 43C-CB0221 | Fitzgerald | 1 mg | EUR 396 |
|
Description: Goat anti Cat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Cat IgG (Alk Phos) |
|||
| 43C-CB0228 | Fitzgerald | 1 mg | EUR 382 |
|
Description: Rabbit anti Cat IgG secondary antibody (Alk Phos) |
|||
Goat anti Cat IgG (Alk Phos) |
|||
| 43C-CB0235 | Fitzgerald | 1 mg | EUR 378 |
|
Description: Goat anti Cat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Chicken IgG (Alk Phos) |
|||
| 43C-CB0321 | Fitzgerald | 1 mg | EUR 399 |
|
Description: Rabbit anti Chicken IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Chicken IgG (Alk Phos) |
|||
| 43C-CB0328 | Fitzgerald | 1 mg | EUR 395 |
|
Description: Rabbit anti Chicken IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Dog IgG (Alk Phos) |
|||
| 43C-CB0414 | Fitzgerald | 1 mg | EUR 399 |
|
Description: Rabbit anti Dog IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Dog IgG (Alk Phos) |
|||
| 43C-CB0421 | Fitzgerald | 1 mg | EUR 382 |
|
Description: Rabbit anti Dog IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0528 | Fitzgerald | 1 mg | EUR 382 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0535 | Fitzgerald | 1 mg | EUR 375 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0542 | Fitzgerald | 500 µg | EUR 392 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0949 | Fitzgerald | 1 mg | EUR 439 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0956 | Fitzgerald | 1 mg | EUR 375 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgG (Alk Phos) |
|||
| 43C-CB0963 | Fitzgerald | 1 mg | EUR 361 |
|
Description: Goat anti Human IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0970 | Fitzgerald | 1 mg | EUR 375 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgG (Alk Phos) |
|||
| 43C-CB0978 | Fitzgerald | 1 mg | EUR 403 |
|
Description: Goat anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgM (Alk Phos) |
|||
| 43C-CB0999 | Fitzgerald | 1 mg | EUR 380 |
|
Description: Goat anti Human IgM secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1142 | Fitzgerald | 1 mg | EUR 389 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1149 | Fitzgerald | 1 mg | EUR 481 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1156 | Fitzgerald | 1 mg | EUR 361 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1163 | Fitzgerald | 1 mg | EUR 452 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgG (Alk Phos) |
|||
| 43C-CB1249 | Fitzgerald | 1 mg | EUR 405 |
|
Description: Rabbit anti Rat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgG (Alk Phos) |
|||
| 43C-CB1256 | Fitzgerald | 1 mg | EUR 399 |
|
Description: Rabbit anti Rat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgM (Alk Phos) |
|||
| 43C-CB1270 | Fitzgerald | 1 mg | EUR 458 |
|
Description: Rabbit anti Rat IgM secondary antibody (Alk Phos) |
|||
Goat anti Rat IgM (Alk Phos) |
|||
| 43C-CB1277 | Fitzgerald | 1 mg | EUR 467 |
|
Description: Goat anti Rat IgM secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1328 | Fitzgerald | 1 mg | EUR 405 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1335 | Fitzgerald | 500 µg | EUR 470 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1342 | Fitzgerald | 1 mg | EUR 396 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1349 | Fitzgerald | 500 µg | EUR 469 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Outcomes confirmed that top Cu publicity precipitated hepatocellular G0/G1 cell-cycle arrest (CCA) and lowered cell proportion within the G2/M part. G0/G1 CCA occurred with down-regulation (p < 0.05) of Ras, p-PI3K (Tyr458), p-Akt (Thr308), p-forkhead field O3 (FOXO3A) (Ser253), p-glycogen synthase kinase 3-β (GSK3-β) (Ser9), murine double minute 2 (MDM2) protein, and mRNA expression ranges, and up-regulation (p < 0.05) of PTEN, p-p53 (Ser15), p27, p21 protein, and mRNA expression ranges, which subsequently suppressed (p < 0.05) the protein and mRNA expression ranges of CDK2/Four and cyclin E/D. These outcomes point out that Cu publicity suppresses the Ras/PI3K/Akt signaling pathway to scale back the extent of CDK2/Four and cyclin E/D, that are important for the G1-S transition, and eventually causes hepatocytes G0/G1 CCA.
